GLP-1 RAs are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with metformin.

Weight-loss jabs could help minimise asthma symptoms in obese people, according to a study. The drugs should be explored as a ...

WEIGHT loss jabs could help control asthma symptoms in obese people, a study suggests – and it’s not just about losing weight ...

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

Common medicines, including diabetes, cancer, and antiviral drugs, may offer new hope in slowing dementia. UK researchers, including a team from the University of Cambridge, have uncovered strong ...

GLP-1s - which mimic the effects of the hormone that stimulates insulin release, suppressing glucagon, and slowing gastric emptying - also have a range of other benefits.

FAT jabs are better than widely prescribed metformin when it comes to curbing dementia risk in people with type 2 diabetes, ...

A new study suggests that drugs like Ozempic and Mounjaro may reduce dementia risk. Researchers at the University of Galway found a 45% lower risk in ...

Weight loss jabs such as Wegovy and Mounjaro may offer a protective effect against dementia and stroke, according to a new study.

Researchers found that the active ingredient in Ozempic may lower the risk of dementia in people with type 2 diabetes.

Newly published research claims those taking GLP-1 jabs are at a 37 percent lower risk of dementia than those on the ...